Guggenheim Reiterates Buy Rating on Guardant Health, Inc.
Guggenheim maintains its buy rating and sets a $160 target for Guardant Health, a 6.65% upside from the current price.
Key Points
- On June 29, 2026, Guggenheim reiterated its buy rating on Guardant Health, Inc. (GH) with a price target of $160.
- Guggenheim's $160 price target implies 6.65% upside from Guardant Health, Inc.'s ($GH) current $150.03 share price.
- Shares of GH traded at $149.22 on Monday, with a market cap of approximately $19.79 billion and a 52-week high of $151.85.
- Other analysts like Bernstein and Barclays also maintain a positive outlook, highlighting strong institutional interest in Guardant Health.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on Guardant Health, Inc. (NasdaqGS: GH) on June 29, 2026. The firm set a price target of $160 for the precision oncology company. Shares of Guardant Health traded at $149.22 on Monday.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its buy rating on Guardant Health, Inc. with a $160 price target. Bernstein also reinstated a buy rating with a target of $175 on June 26, 2026. Barclays maintained its buy rating with a $150 target on June 24, 2026. Other firms like RBC Capital and Goldman Sachs also show strong buy ratings, with targets of $185 and $165, respectively.
Other Institutional Activity in Guardant Health
BLACKROCK, INC. grew its holdings by 236,045 shares, ending with 11,553,759 shares worth about $1.07 billion. PRICE T ROWE ASSOCIATES INC /MD/ increased its position by 1,387,611 shares, bringing its total to 7,023,689 shares valued at approximately $648.78 million. VANGUARD PORTFOLIO MANAGEMENT LLC and VANGUARD CAPITAL MANAGEMENT LLC both opened new positions, holding 5,837,992 and 5,624,180 shares, respectively. Meanwhile, INVESCO LTD. reduced its stake by 369,465 shares, now holding 4,946,469 shares valued at about $456.91 million.
Guardant Health, Inc. Stock Down 7.1%
Shares of NasdaqGS:GH traded near $149.22 on Monday. Guardant Health has a market cap of approximately $19.79 billion. The company's forward P/E ratio is not meaningful as it is not currently profitable, with a beta of 1.619. The stock's 52-week low is $40.35, and its 52-week high is $151.85. It also has a 50-day moving average of $111.18 and a 200-day moving average of $95.82.
$GH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Guardant Health, Inc.
On June 22, 2026, insiders Tariq Musa and Myrtle Potter planned sales of 1,951 and 1,556 shares, respectively, at an average price of $131.16. Roberto Mignone had several transactions, both buying and selling 264 shares, without a disclosed price, on June 21 and May 21, 2026.
About Guardant Health, Inc.
Guardant Health, Inc. is a healthcare company specializing in precision oncology. Based in Palo Alto, California, it provides blood and tissue tests, including the Guardant360 CDx and Guardant360 Liquid tests, which offer insights into tumor genetics. The company also offers the Guardant Reveal test for early cancer detection and the GuardantINFINITY test for comprehensive tumor profiling. Led by CEO Dr. Helmy Eltoukhy, the company employs about 2,490 people.
Bottom Line
Guardant Health continues to attract interest from analysts and institutional investors, with Guggenheim and others maintaining strong buy ratings. The company's stock performance and innovative cancer detection technologies make it a closely watched player in the healthcare sector. Investors should note that analyst ratings are forward-looking and subject to change.
Get Guardant Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.